Physician profile
Charles Rust
NPI 1457435752
$7,697.66
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $2,458 · 2021: $2,682 · 2022: $363.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $954.18 | 2019-2022 | |
| Amarin Pharma, INC. | $663.85 | 2019-2021 | |
| Optinose US, INC. | $655.21 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $574.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.71 | 2019-2022 | |
| Abbvie INC. | $550.96 | 2019-2021 | |
| Lilly USA, LLC | $489.78 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $313.61 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $303.81 | 2020-2021 | |
| Daiichi Sankyo INC. | $279.21 | 2019-2021 | |
| Glaxosmithkline, LLC. | $262.02 | 2019-2022 | |
| Eisai INC. | $218.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.44 | 2019-2021 | |
| Allergan, INC. | $210.64 | 2019-2020 | |
| Pfizer INC. | $152.44 | 2020-2022 |
Show all 43 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.